Summary of the Conference Call for 康诺亚 Company Overview - 康诺亚 is a leading company focused on autoimmune diseases, with core products including CM310 (思普曲帕单抗) and the next-generation dual antibody CM512 [2][3]. Key Products and Market Potential - **CM310 (思普曲帕单抗)**: - Recently included in the medical insurance directory, expected to see rapid market growth [2]. - Approved for three indications: adult moderate to severe atopic dermatitis, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis, with plans to expand to adolescents and children [2][3]. - Clinical trial results show a 52-week EASI75 response rate of 92.5% and EASI90 response rate of 77% in adult atopic dermatitis patients [4]. - In chronic rhinosinusitis, 90% of patients showed at least a 50% reduction in nasal polyps after 52 weeks [5]. - For seasonal allergic rhinitis, approximately 84% of patients experienced relief from nasal symptoms, and 94% from ocular symptoms [6]. - **CM512**: - A next-generation dual antibody targeting TSLP and IL-13, with a half-life of 70 days, allowing for dosing every three months [3][7]. - Phase I data shows EASI75 and EASI90 response rates of 58.3% and 41.7% respectively at 12 weeks, indicating competitive advantages over existing therapies [3][8]. - **CMG901 (Claudin 18.2 ADC)**: - Leading in the development for gastric and pancreatic cancer, with a phase III trial expected to complete by October 2026 [3][9]. - Early data shows a PFS of 4.8 months and OS of 11.8 months, indicating promising market potential [9]. Financial Projections - Revenue for CM310 is projected to grow rapidly, from approximately 300 million RMB in 2025 to about 750 million RMB in 2026 [10]. - Overall revenue estimates for 康诺亚 from 2025 to 2027 are 637 million, 764 million, and 480 million RMB, with year-on-year growth rates of 47%, 21%, and 94% respectively [10]. Valuation - Using a DCF model, 康诺亚's valuation is estimated at approximately 24.5 billion RMB, with a target price increase of 82%, leading to a buy rating [11]. Additional Insights - CM310 shows lower relapse rates and better safety and tolerability compared to Sanofi's Dupilumab, with a relapse rate of approximately 0.9% after 52 weeks [4]. - The company is positioned strongly in the market due to its innovative products and competitive advantages over existing therapies [7].